Phase 2 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Myasthenia Gravis (MG).
- You are eligible to receive the study drug efgartigimod based on your country's approved guidelines, confirmed by a blood test at the start of the study.
- Your MG symptoms are measured using a specific scoring system (MG-ADL), and your score falls within a certain range that shows a meaningful level of difficulty with daily activities (confirm with trial site for exact score details).
Who may not be able to join:
- You have another active immune system disease (such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, Sjögren's syndrome, or scleroderma) or an immune deficiency condition, whether inherited or caused by medication.
- You have previously tried a similar type of treatment (called an FcRn treatment) and it either did not work for you or caused safety concerns.
- You have ever received certain specific treatments that affect your immune system, including B-cell depleting therapies, alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy, or natalizumab.
- You have seriously reduced function in one or more of your major organs (confirm with trial site).
- You have had a severe or life-threatening allergic reaction to any of the medications used in this trial, including the study drugs or required pre-treatment medications.
- You are unwilling or unable to follow the study procedures and required follow-up visits.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-575-8489
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to Onset of a Clinical Worsening Event
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.